Palvella Therapeutics (PVLA) Short term Debt (2013 - 2014)
Palvella Therapeutics (PVLA) posted quarterly Short term Debt of $1.3 million for Q4 2014, up 515.33% year-over-year from $206490.0 in Q4 2013, and up 36474.7% quarter-over-quarter from $3474.0 in Q3 2014.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Short term Debt (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Short term Debt for 2 consecutive years, with $1.3 million the latest figure, recorded in Q4 2014.
- In Q4 2014, Short term Debt rose 515.33% year-over-year to $1.3 million; the TTM figure through Dec 2014 stood at $1.3 million (up 515.33% YoY), while the FY2014 annual figure was $1.3 million, up 515.33% from the prior year.
- Short term Debt advanced to $1.3 million in Q4 2014 per PVLA's latest filing, from $3474.0 in the prior quarter.
- Across five years, Short term Debt topped out at $1.3 million in Q4 2014 and bottomed at $474.0 in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 3,474.00 |
| Jun 30, 2014 | 474.00 |
| Dec 31, 2013 | 206,490.00 |